Andres E Dulcey

US Patent:

20210101872, Apr 8, 2021

Filed:

Mar 8, 2019

Appl. No.:

16/976012

Inventors:

- Bethesda MD, US
- Santiago, CL
Noel T. Southall - Potomac MD, US
Andres E. Dulcey - Gaithersburg MD, US
Xin Hu - Frederick MD, US
Christopher R. Dextras - Frederick MD, US
Daniel C. Talley - Baltimore MD, US
Alejandra Alvarez - Santiago, CL
Silvana Zanlungo - Santiago, CL
Rommy M. Von Bernhardi - Santiago, CL

Assignee:

The USA, as represented by the Secretary, Dept. of Health and Human Services - Bethesda MD
Pontificia Universidad Católica de Chile - Santiago

International Classification:

C07D 243/38
C07D 267/20
C07F 7/08
C07D 281/16
C07D 267/18
C07C 227/22
C07C 201/12
C07C 319/14
C07D 401/04
C07D 403/04
C07D 413/10
C07F 5/02
C07D 413/04
C07D 471/04
C07D 487/04
C07D 413/14
C07D 417/04
A61P 33/06
A61P 25/28
A61P 25/08
A61P 35/02
A61K 31/554
A61K 31/5513
A61K 31/553

Abstract:

Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.